AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trial
阿斯利康体内CAR-T疗法在manbetx3.0 试验中出现早期应答，但发生一例死亡

New clinical trial data on the in vivo CAR-T therapy that AstraZeneca acquired last year suggest that while the experimental treatment can curb multiple myeloma in some patients, it may not be safer than the cell therapies engineered in a lab.
阿斯利康去年收购的体内CAR‑T疗法的最新临床试验数据显示：这种实验性治疗虽可在部分患者中遏制多发性骨髓瘤，但其安全性或并不优于在实验室中工程化制备的细胞疗法。